Polypeptides that bind ox40 and uses thereof

By designing peptides containing the VHH domain to bind with OX40 to form multivalent conjugates, the problem of insufficient efficiency of OX40 agonists is solved, significantly enhancing T cell activation and immune response, and effectively fighting cancer.

CN112601761BActive Publication Date: 2026-06-12INHIBI BIOSCIENCE CO LTD
9 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
INHIBI BIOSCIENCE CO LTD
Filing Date
2019-08-12
Publication Date
2026-06-12

AI Technical Summary

⚠Technical Problem

Existing OX40 agonists are inefficient and cannot effectively regulate T cell activation, resulting in an insufficient immune response to diseases such as cancer.

⚗Method used

Develop peptides containing the VHH domain that, by binding to OX40, enhance the proliferation, expression, and function of T cells, forming multivalent conjugates to improve agonist efficacy.

🎯Benefits of technology

It significantly enhances the proliferation of CD4+ and CD8+ T cells, CD25 and CD71 expression, and NFκB signaling, increases IFNγ expression, and enhances the immune response against cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The present invention provides VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind OX40 and agonize OX40 are provided. Uses of VHH-containing polypeptides are also provided.
Need to check novelty before this filing date? Find Prior Art